Expression of Dominant-negative Fas-associated Death Domain Blocks Human Keratinocyte Apoptosis and Vesication Induced by Sulfur Mustard*

Dean S. RosenthalDagger §, Alfredo VelenaDagger , Feng-Pai ChouDagger , Richard Schlegel, Radharaman Ray||, Betty Benton||, Dana Anderson||, William J. Smith||, and Cynthia M. Simbulan-RosenthalDagger

From the Departments of Dagger  Biochemistry and Molecular Biology and  Pathology, Georgetown University School of Medicine, Washington, D. C. 20007 and the || United States Army Medical Research Institute of Chemical Defense, Aberdeen Proving Ground, Maryland 21010

Received for publication, September 17, 2002, and in revised form, December 2, 2002

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

DNA damaging agents up-regulate levels of the Fas receptor or its ligand, resulting in recruitment of Fas-associated death domain (FADD) and autocatalytic activation of caspase-8, consequently activating the executioner caspases-3, -6, and -7. We found that human epidermal keratinocytes exposed to a vesicating dose (300 µM) of sulfur mustard (SM) exhibit a dose-dependent increase in the levels of Fas receptor and Fas ligand. Immunoblot analysis revealed that the upstream caspases-8 and -9 are both activated in a time-dependent fashion, and caspase-8 is cleaved prior to caspase-9. These results are consistent with the activation of both death receptor (caspase-8) and mitochondrial (caspase-9) pathways by SM. Pretreatment of keratinocytes with a peptide inhibitor of caspase-3 (Ac-DEVD-CHO) suppressed SM-induced downstream markers of apoptosis. To further analyze the importance of the death receptor pathway in SM toxicity, we utilized Fas- or tumor necrosis factor receptor-neutralizing antibodies or constructs expressing a dominant-negative FADD (FADD-DN) to inhibit the recruitment of FADD to the death receptor complex and block the Fas/tumor necrosis factor receptor pathway following SM exposure. Keratinocytes pretreated with Fas-blocking antibody or stably expressing FADD-DN and exhibiting reduced levels of FADD signaling demonstrated markedly decreased caspase-3 activity when treated with SM. In addition, the processing of procaspases-3, -7, and -8 into their active forms was observed in SM-treated control keratinocytes, but not in FADD-DN cells. Blocking the death receptor complex by expression of FADD-DN additionally inhibited SM-induced internucleosomal DNA cleavage and caspase-6-mediated nuclear lamin cleavage. Significantly, we further found that altering the death receptor pathway by expressing FADD-DN in human skin grafted onto nude mice reduces vesication and tissue injury in response to SM. These results indicate that the death receptor pathway plays a pivotal role in SM-induced apoptosis and is therefore a target for therapeutic intervention to reduce SM injury.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Sulfur mustard (bis-(2-chloroethyl) sulfide; SM),1 the vesicant agent used as recently as 1988/1989 in the Iraq/Iran conflict and implied to have been used in the Gulf War, induces vesication in human skin by its ability to cause cytotoxic, genotoxic, or a combination of both effects in the skin. SM is a highly reactive compound that induces the death and detachment of the basal cells of the epidermis from the basal lamina (1-6). SM causes blisters in the skin via poorly understood mechanisms. In an effort to help develop medical countermeasures for potential exposure of military personnel and civilians, we have been attempting to define the molecular series of events leading to SM toxicity in cell culture, in transgenic animal models, and in grafted human epidermis.

Whereas human dermal fibroblasts may contribute to the vesication response by releasing degradative cytosolic components extracellularly after a poly(ADP-ribose) polymerase (PARP)-dependent SM-induced necrosis (7), keratinocytes display markers of an apoptotic death, as well as those of terminal differentiation (8). SM-induced apoptosis in keratinocytes appears to be controlled by both death receptor and mitochondrial pathways (9). The targets of these apoptotic pathways are a family of aspartate-specific cysteine proteases or caspases (10). Caspase-3 appears to be a converging point for different apoptotic pathways (11). In most apoptotic systems, caspase-3 is proteolytically activated, and in turn cleaves key proteins involved in the structure and integrity of the cell, including PARP (11-14).

In the present study, we demonstrate that SM induces both Fas and its ligand (FasL) in primary human epidermal keratinocytes. We also observed the activation of markers of apoptosis that are consistent with a Fas-FasL-receptor interaction, including cleavage of caspase-8, caspase-3, and PARP. Utilizing a combination of techniques including the stable expression of a dominant-negative inhibitor of Fas-associated death domain protein (FADD), we demonstrate a role for the Fas/TNF receptor family in mediating the response of human keratinocytes to SM. Stable expression of FADD-DN blocks SM-induced markers of keratinocyte apoptosis, such as caspase-3 activity and proteolytic processing of procaspases-3, -7, and -8, internucleosomal DNA cleavage, and caspase-6-mediated nuclear lamin cleavage.

We have shown earlier that NHEK as well as an immortalized line, Nco, could be used to establish a histologically and immunocytochemically normal epidermis when grafted onto nude mice (8, 9, 15). The present study demonstrates that markers of apoptosis are induced in basal cells of SM-exposed grafts, particularly in regions where microvesicles are formed. We have now also utilized the graft system to genetically engineer human keratinocytes prior to grafting to ectopically express a dominant-negative FADD and generate a human epidermis containing FADD-DN keratinocytes. These human grafts were exposed to SM, and showed a reduced vesication response compared with control keratinocyte. Topical SM exposure of Fas-deficient mice in the current study also indicates the viability of this strategy to suppress vesication by using inhibitors of the death receptor pathway.

An understanding of the mechanisms for SM vesication will hopefully lead to therapeutic strategies for prevention or treatment of SM toxicity. Importantly, our experiments indicate that the Fas/FADD pathway is required for caspase-3 processing, because inhibitors of this pathway block SM-induced apoptosis. Because the FADD pathway can be manipulated at the level of a cell surface (Fas), receptor, Fas/FADD as well as the caspases represent attractive targets for the modulation of the effects of SM. Inhibition of the Fas/FADD pathway by specific pharmacological inhibitors such as neutralizing antibodies to Fas or peptide inhibitors of caspases may therefore be of therapeutic value in the treatment of or prophylaxis against SM injury in humans.

    MATERIALS AND METHODS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Cells, Plasmids, and Transfection-- Primary human keratinocytes were derived from neonatal foreskins and grown in keratinocyte serum-free medium (SFM) supplemented with human recombinant epidermal growth factor and bovine pituitary extract (Invitrogen). Primary keratinocytes were immortalized by transduction with the HPV16 E6/E7 genes (16) to generate the Nco cell line as described previously (17). The FADD-DN plasmid construct in pcDNA 3.1 (Invitrogen), a generous gift from Dr. V. Dixit, expresses a truncated FADD protein, which lacks the N-terminal domain that is responsible for recruiting and activating caspase-8 at the death receptor complex (Fig. 5A). Nco cells were transfected with empty vector or with FADD-DN using LipofectAMINE (Invitrogen), and stable clones were selected in G418 and maintained in SFM. Cells were grown to 60-80% confluency, and then exposed to SM diluted in SFM to final concentrations of 100, 200, or 300 µM, with or without pretreatment with Fas- (clone ZB-4; Upstate Biotech, Waltham, MA) or TNFR1- (clone H398; Bender MedSystems, Vienna, Austria (18)) neutralizing antibodies. Media was not changed for the duration of the experiments. At different time points after SM exposure, cells were harvested for further analyses.

Chemicals-- SM (bis-(2-chloroethyl) sulfide; >98% purity) was obtained from the United States Army Edgewood Research, Development and Engineering Center.

Fluorometric Assay of Caspase-3 Activity-- Cells were resuspended in lysis buffer containing 50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1 mM EGTA, 0.25% sodium deoxycholate, 0.5% Nonidet P-40, 10 µg/ml aprotinin, 20 µg/ml leupeptin, 10 µg/ml pepstatin A, and 1 mM phenylmethylsulfonyl fluoride, incubated for 10 min on ice, and freeze-thawed 3 times. The cell lysate was centrifuged at 14,000 × g for 5 min, and the protein concentration of the cytosolic extract was determined with the Bio-Rad DC protein assay kit. For the fluorometric caspase-3 activity assay, 25 µg of cytosolic extract was initially diluted to a volume of 50 µl with Nonidet P-40 lysis buffer, to which 50 µl of caspase assay buffer (10 mM HEPES (pH 7.4), 2 mM EDTA, 0.1% CHAPS, 5 mM dithiothreitol) was added. The aliquots were then mixed with equal amounts (100 µl) of 40 µM fluorescent tetrapeptide substrate specific for caspase-3 (Ac-DEVD-AMC; BACHEM) in caspase assay buffer and transferred to 96-well plates. Free aminomethylcoumarin (AMC), generated as a result of cleavage of the aspartate-AMC bond, was monitored continuously over 10 min with a Cytofluor 4000 fluorometer (PerSeptive Biosystems, Framingham, MA) at excitation and emission wavelengths of 360 and 460 nm, respectively. The emission from each well was plotted against time, and linear regression analysis of the initial velocity (slope) for each curve yielded the activity.

Immunoblot Analysis-- SDS-PAGE and transfer of separated proteins to nitrocellulose membranes were performed according to standard procedures. Proteins were measured (DCA protein assay; Bio-Rad) and normalized prior to gel loading, and all filters were stained with Ponceau S, to reduce the possibility of loading artifacts. They were then incubated with antibodies to the p17 subunit of caspase-3 (1:200; Santa Cruz Biotechnology), caspase-7 (1:1000; BD Pharmingen), caspase-8 (1:1000; BD Pharmingen), caspase-9 (1:1000; Trevigen), or caspase-10 (1:1000; Trevigen), lamin A (1:100; Santa Cruz Biotechnology), DNA fragmentation factor (DFF) 45 (1:500; BD Pharmingen), or PARP (1:1000; BD Pharmingen). Immune complexes were detected by subsequent incubation with appropriate horseradish peroxidase-conjugated antibodies to mouse or rabbit IgG (1:3000) and enhanced chemiluminescence (Pierce). Immunoblots were sequentially stripped of antibodies by incubation for 30 min at 50 °C with a solution containing 100 mM 2-mercaptoethanol, 2% SDS, and 62.5 mM Tris-HCl (pH 6.7), blocked again, and reprobed with additional antibodies to accurately compare different proteins from the same filter. Typically, a filter could be reprobed three times before there was detectable loss of protein from the membrane, which was monitored by Ponceau S staining after stripping.

Analysis of DNA Fragmentation-- Cells were harvested and lysed in 0.5 ml of 7 M guanidine hydrochloride, and total genomic DNA was extracted and purified using a Wizard Miniprep DNA Purification Resin (Promega). After RNase A treatment (20 µg/ml) of the DNA samples for 30 min, apoptotic internucleosomal DNA fragmentation was detected by gel electrophoresis on a 1.5% agarose gel at 4 V/cm. DNA ladders were visualized by staining with ethidium bromide (0.5 µg/ml) and images were captured with the Kodak EDAS 120 (Kodak) gel documentation system.

Annexin V and Propidium Iodide Staining, and FACS Analysis-- Cells were plated in culture plates and exposed to various concentrations of SM. 16 h after induction of apoptosis, the cells were trypsinized, washed with ice-cold phosphate-buffered saline (PBS), and subsequently resuspended in and incubated in the dark with 100 µl of annexin V incubation reagent that includes fluorescein isothiocyanate-conjugated annexin V (Trevigen, Gaithersburg, MD) and propidium iodide for 15 min at room temperature. Flow cytometric analyses were conducted on a BD Biosciences FACStar Plus cytometer using a 100-milliwatt air-cooled argon laser at 488 nm.

Grafting Protocols and Exposure of Human Skin Grafts to SM-- A 1-cm diameter piece of skin was removed from the dorsal surface of athymic mice, and a pellet of cells containing 8 × 106 fibroblasts + 5 × 106 keratinocytes (NHEK or Nco) was pipetted on top of the muscular layer within a silicon dome to protect the cells during epithelization (Fig. 10A). The dome was removed after a week and the graft was allowed to develop for 6-8 weeks. SM exposure was performed by placing a small amount of SM liquid into an absorbent filter at the bottom of a vapor cup, which was then inverted onto the dorsal surface of the animal, to expose the graft site to the SM vapor. Frozen and fixed sections were derived from punch biopsies taken from the graft site, and analyzed for the expression of FADD-DN using the AU1 antibody, which recognizes the specific AU1 epitope tag on the FADD-DN protein. Histological analysis of the SM-exposed human skin grafts transplanted onto nude mice was also performed utilizing an end point of micro- or macroblisters or SM-induced microvesication.

Assays for in Vivo Markers of Apoptosis on Human Skin Grafts-- Paraffin-embedded sections derived from SM-exposed human skin grafts were subjected to analysis for markers of in vivo apoptosis, including indirect immunofluorescence microscopy with antibodies to the active form of caspase-3 (Cell Signaling Technology, Beverly, MA). Sections were deparaffinized, incubated overnight in a humid chamber at room temperature with antibodies to active caspase-3 (1:250 dilution) in PBS containing 12% bovine serum albumin. After a PBS wash, slides were incubated for 1 h with biotinylated anti-mouse IgG (1:400 dilution in PBS/bovine serum albumin), washed, and incubated for 30 min with streptavidin-conjugated Texas Red (1:800 dilution in PBS/bovine serum albumin). Cells were finally mounted with PBS containing 80% glycerol and observed with a Zeiss fluorescence microscope.

DNA breaks characteristic of the late stage of apoptosis were detected in situ using a Klenow fragment-based assay system (DermaTACS; Trevigen). For fixation, slides were equilibrated to room temperature and redried for 2 h on a slide warmer at 45 °C, rehydrated in 100, 95, then 70% ethanol, washed in PBS, fixed in 3.7% buffered formaldehyde for 10 min at room temperature, and washed in PBS. Slides were then incubated with 50 µl of Cytonin for 30 min at room temperature, washed twice in deionized water, and immersed in quenching solution containing 90% methanol and 3% H2O2 for 5 min at room temperature. After a PBS wash, slides were incubated in terminal deoxynucleotidyltransferase labeling buffer for 5 min at room temperature, and visualized under a bright field microscope.

    RESULTS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Characterization of the Sequence of Events during SM-induced Apoptosis-- We determined the sequence of events involved in SM-induced apoptosis by performing dose-response and time course experiments. Fas, a cell-surface receptor found in most cell types including keratinocytes, mediates some forms of apoptosis. Upon activation by its specific ligand (FasL), or by agonist antibody, Fas forms a homotrimeric complex, which in turn recruits the FADD to the membrane-bound complex. In turn, one or more of the upstream caspases (caspase-8 or -10) localize to the Fas-FADD complex, and become autocatalytically activated. We first determined whether SM induces expression of the Fas receptor or its ligand because enhanced expression of Fas or FasL has been shown to occur in cells exposed to DNA damaging agents, leading to activation of upstream caspase-8 and downstream apoptotic events such as caspase-3-mediated PARP cleavage (19, 20). Immunoblot analysis of extracts derived from keratinocytes exposed to different doses of SM revealed a dose-dependent increase in the levels of both Fas receptor and FasL in response to SM (Fig. 1A).


View larger version (33K):
[in this window]
[in a new window]
 
Fig. 1.   Exposure of human keratinocytes to SM results in a dose-dependent up-regulation of Fas and FasL expression, caspase-8 activation, and caspase-3-mediated PARP cleavage. Human keratinocytes (NHEK) were incubated for 16 h with the indicated concentrations of SM in SFM (A-C) or agonistic Fas antibody (C), after which cell extracts were prepared and assayed for the presence of Fas and FasL (A), and proteolytic cleavage of caspase-8 (B) or PARP (C) by immunoblot analysis. The positions of molecular size standards (in kilodaltons) and of the various proteins are indicated.

By immunoblot analysis using antibodies that recognize both the full-length (116 kDa) and 89-kDa cleavage products of PARP, we also demonstrated that SM-induced apoptosis is accompanied by complete cleavage of PARP into 89- and 24- kDa fragments that contain the active site and the DNA-binding domain of the enzyme, similar to the caspase-3-mediated cleavage of PARP induced by exposure to anti-Fas (Fig. 1C).

The central signaling proteins for many of the pathways that coordinate apoptosis are the caspases, cysteine proteases named for their preference for aspartate at their substrate cleavage site (10), which cleave key proteins involved in the structure and integrity of the cell. We previously focused on caspase-3 activation in the SM apoptotic response (8, 9), because caspase-3 has been shown to be a converging point for different apoptotic pathways (11). In a number of apoptotic systems, caspase-3 cleaves key proteins involved in the structure and integrity of the cell. To further understand the apoptotic response of keratinocytes following SM exposure, we assayed for the activation of other key caspases, in particular the upstream caspases-8, -9, and -10, and the executioner caspases-3, -6, and -7. When the blot in Fig. 1A was stripped of antibodies and reprobed with anti-caspase-8, SM-induced proteolytic processing of caspase-8 was noted in cells exposed to vesicating doses of SM (200 and 300 µM; Fig. 1B).

The sequence of caspase activation provides insight into the mechanism of apoptosis because caspase-8 is first activated following engagement of death receptors, whereas caspase-9 is activated via a mitochondrial pathway. We therefore investigated the molecular ordering of caspase activation in response to SM. NHEK were exposed to 300 µM SM for various times, and cell extracts were derived and subjected to immunoblot analysis utilizing antibodies specific to caspases-3, -7, -8, -9, or -10. Upstream caspases-8 and -9 were both activated in a time-dependent fashion, with caspase-8 cleaved prior to caspase-9 (1 versus 4 h) (Fig. 2). Because activation of caspase-8 correlates with a Fas-mediated pathway of apoptosis and activation of caspase-9 is consistent with a mitochondrial pathway, these results are in agreement with the activation of both death receptor and mitochondrial pathways by SM. In contrast, no cleavage of caspase-10 was observed (Fig. 6C).


View larger version (28K):
[in this window]
[in a new window]
 
Fig. 2.   Exposure of human keratinocytes to SM induces proteolytic processing of procaspases-8, -9, -3, and -7 in a time-dependent fashion. Human keratinocytes (NHEK) were incubated with 300 µM SM in SFM and, after the indicated times, cell extracts were prepared and assayed for the proteolytic cleavage and activation of upstream caspases-8 and -9, as well as effector caspases-3 and -7 by immunoblot analysis. The positions of the various procaspases and their cleavage products (for caspases-3 and -9) are indicated.

The executioner caspases-3 and -7 were both proteolytically activated after SM exposure, with caspase-3 activation detectable 3 h after SM exposure, and caspase-7 cleavage noted 4 h after exposure. To detect caspase-6 activity, we utilized antisera specific for lamin A, which is cleaved in vivo by active caspase-6 at the peptide sequence VEID. Caspase-6 activity is essential for lamin A cleavage, which is necessary for chromatin condensation during apoptotic execution (21). Fig. 3 shows the time course of caspase-6-mediated lamin A cleavage in NHEK following SM exposure. Surprisingly, this substrate was one of the first to be cleaved (within 1 h), relative to cleavage of PARP (6 h), or the apoptotic DFF/inhibitor of caspase-activated DNase (16 h; Fig. 3). PARP has been shown to be a substrate of caspase-3 and -7, whereas DFF 45 is primarily cleaved by caspase-3. Taken together, these data suggest that caspase-6 may be the first of the executioner caspases to be activated following exposure of NHEK to SM, followed by caspase-3 and -7. 


View larger version (26K):
[in this window]
[in a new window]
 
Fig. 3.   Exposure of human keratinocytes to SM induces proteolytic cleavage of downstream targets of caspase-3 (PARP and DFF 45) as well as of caspase-6 (lamin A). NHEK were incubated with 300 µM SM in SFM and, after the indicated times, cell extracts were prepared and assayed for the proteolytic cleavage of downstream targets of caspase-3: PARP and DFF 45, and caspase-6-mediated lamin A cleavage by immunoblot analysis with antibodies specific for these proteins. The positions of the various proteins and their cleavage products are indicated.

Caspase-6-mediated Cleavage of Epidermal Keratin K1 following SM Exposure-- We previously found that the suprabasal-specific keratins, K1 and K10, are induced upon exposure of NHEK to 100 µM SM, using monoclonal antibodies (8). In the current study, we utilized a polyclonal antibody directed against the C terminus of K1, and found that exposure of cells to higher concentrations of SM resulted in proteolytic cleavage of keratin K1 (Fig. 4A). The size of the K1 cleavage product maps near a perfect consensus sequence for a site of cleavage by caspase-6 (Fig. 4B). Moreover, point mutations near this region of K1 give rise to a genetic blistering disorder, epidermolytic hyperkeratosis, very similar to SM-induced vesication (22). K1 may therefore be a substrate for caspase-6 and a target during SM-induced keratinocyte apoptosis.


View larger version (33K):
[in this window]
[in a new window]
 
Fig. 4.   Exposure of human keratinocytes to SM results in a dose-dependent cleavage of epidermal keratin K1. A, NHEK were incubated with 300 µM SM in SFM and, after the indicated time, cell extracts were subjected to immunoblot analysis with antibodies to keratin K1. The positions of K1 and its cleavage product are indicated. B, schematic diagram of the K1 consensus sequence containing a putative site of cleavage by caspase-6 (VEID).

Expression of FADD Dominant-negative in Human Keratinocytes Inhibits SM-induced Activation and Processing of Caspases-3 and -8-- Up-regulation of the Fas ligand or receptor (23) causes recruitment of FADD (24), FLASH (25), and caspase-8 (26), to the death-inducing signaling complex (27), and induces the activation of caspase-8 (26), followed by the activation of the executioner caspases-3, -6, and -7. SM induces a dose-dependent increase in the levels of both Fas receptor as well as FasL (Fig. 1), and caspase-8 is activated within 2 h after exposure of NHEK to SM (Fig. 2). To further analyze the importance of the death receptor pathway for SM toxicity, we utilized a dominant negative inhibitor of FADD (FADD-DN), which expresses a truncated FADD protein containing an AU1 epitope tag and lacking the N-terminal domain necessary for recruitment and activation of caspase-8 at the death receptor complex (Fig. 5A). Thus, the recruitment of FADD to the death receptor complex is inhibited in cells expressing FADD-DN. Nco cells were transfected with empty vector or with FADD-DN; stable clones were selected in G418 and maintained in SFM. Immunoblot analysis of extracts derived from different FADD-DN clones with antibodies to FADD confirmed the presence of both FADD and FADD-DN in positive clones, whereas parental Nco cells expressed only full-length FADD protein (Fig. 5B, left panel). Expression of the AU1 tag in one clone (DN3), which was chosen for high levels of FADD-DN and used in subsequent experiments, was further confirmed by immunoblot analysis with anti-AU1 (Fig. 5B, right panel).


View larger version (25K):
[in this window]
[in a new window]
 
Fig. 5.   Positive clones of human keratinocytes (Nco) stably transfected with FADD-DN express truncated FADD (FADD-DN) and epitope tag AU1. A, schematic representation of FADD, and a dominant-negative inhibitor of FADD (FADD-DN), which expresses a truncated FADD lacking the death effector domain (DED) responsible for recruitment and activation of caspase-8 at the death receptor complex, thereby blocking the recruitment and activity of endogenous FADD. B, Nco cells, derived from NHEK were transfected with empty vector or with FADD-DN, and stable clones were selected in G418. Extracts of different FADD-DN clones were subjected to immunoblot analysis with antibodies to FADD, confirming the presence of both FADD and FADD-DN in positive clones, whereas parental Nco cells expressed only full-length FADD (left panel). Expression of the AU1 tag in one clone (DN3), which was chosen for high levels of FADD-DN and used in subsequent experiments, was confirmed by immunoblot analysis with anti-AU1 (right panel). The positions of FADD and FADD-DN are indicated.

We first tested whether expression of the FADD-DN construct could in fact suppress the death receptor pathway of apoptosis. Control Nco (transfected with vector alone) or Nco stably expressing FADD-DN were incubated with a Fas agonist antibody (clone CH11) to induce apoptosis. We measured caspase-3 activity as a marker of apoptosis, by quantitative fluorometric analysis with DEVD-AMC as a substrate. Cytosolic extracts were derived 16 h after SM exposure and analyzed for caspase-3 activity. Fig. 6A (right panel) shows that, following incubation with agonist antibodies to Fas, caspase-3 activity is suppressed in cells expressing the FADD-DN protein. Control Nco and Nco-FADD-DN keratinocytes were then treated with increasing doses of SM for 16 h, and extracts were analyzed for caspase-3 activity. Similar to Fas-mediated apoptosis, SM-induced caspase-3 activity was markedly inhibited by expression of FADD-DN (Fig. 6A, left panel). At all SM doses, Nco keratinocytes displayed substantially more caspase-3 activity than cells expressing FADD-DN.


View larger version (40K):
[in this window]
[in a new window]
 
Fig. 6.   Stable expression of FADD-DN in Nco keratinocytes inhibits SM-induced activation and proteolytic processing of procaspases-3 and -8 to their active forms. A, Nco and FADD-DN keratinocytes were incubated for 16 h with the indicated concentrations of SM in SFM (left panel) or to agonist antibodies to Fas (right panel), after which whole cell extracts were prepared and assayed for caspase-3 activity with the specific substrate DEVD-AMC. Cell extracts from the experiment in A were subjected to immunoblot analysis with antibodies specific for caspases-3 (B), -8, and -10 (C). The positions of the caspases and their proteolytic cleavage products are indicated.

We next analyzed whether expression of FADD-DN in keratinocytes could suppress the proteolytic processing of procaspase-3 into its catalytically active form. An immunoblot analysis was performed, using an antibody specific for the larger subunits (p17/p20) of active caspase-3. Fig. 6B shows that treatment of control Nco keratinocytes with 100, 200, or 300 µM SM resulted in the dose-dependent increase in processing of procaspase-3 into the active p17/p20 forms. On the other hand, this processing was almost completely suppressed in cells stably expressing FADD-DN.

To further analyze the effects of FADD-DN on caspase processing, cells were exposed to SM and extracts were harvested after the indicated times and analyzed for the proteolytic cleavage of procaspase-8. Immunoblot analysis with antibodies to the intact form of caspase-8 revealed that proteolytic activation of caspase-8 is suppressed in FADD-DN keratinocytes (Fig. 6C). Caspase-8 processing can clearly be observed as early as 2 h after SM exposure in control Nco cells but not in the FADD-DN keratinocytes. As expected, caspase-10 is not activated during SM-induced apoptosis.

FADD Dominant-negative Expression in Keratinocytes Inhibits SM-induced Internucleosomal DNA Fragmentation and Caspase-6-mediated Lamin Cleavage-- A hallmark of apoptosis is the generation of multimers of nucleosome-sized DNA fragments as the result of the activation of apoptotic endonucleases, which cleave the chromatin in the internucleosomal linker region. We treated Nco or Nco-FADD-DN keratinocytes with increasing concentrations of SM, after which DNA was isolated and resolved on 1.5% agarose gels. Fig. 7A shows that SM-induced internucleosomal DNA fragmentation is clearly visible in control Nco keratinocytes even at lower concentrations of SM, but not in those expressing FADD-DN. At higher SM concentrations, a characteristic apoptotic pattern of internucleosomal cleavage was observed in SM-exposed control Nco cells, whereas DNA extracted from FADD-DN cells appeared as a smear, characteristic of necrotic death.


View larger version (56K):
[in this window]
[in a new window]
 
Fig. 7.   Stable expression of FADD-DN in Nco keratinocytes inhibits SM-induced internucleosomal DNA fragmentation and caspase-6-mediated lamin cleavage. A, control keratinocytes, or Nco stably expressing FADD-DN were exposed to the indicated concentrations of SM in SFM for 16 h, after which total genomic DNA was extracted, purified, and apoptotic internucleosomal DNA fragmentation was detected by gel electrophoresis on a 1.5% agarose gel and ethidium bromide staining. B, cell extracts from the experiment in A were subjected to immunoblot analysis with antibodies to lamin A. The positions of lamin A and its cleavage product are indicated.

Another well established marker of apoptosis is the fragmentation of nuclei, which occurs partly because of the caspase-6-mediated cleavage of nuclear lamin A at a specific sequence (21). We therefore analyzed the cleavage of lamin A following exposure to SM. Whereas control Nco keratinocytes displayed a dose-dependent increase in the caspase-6-mediated cleavage of lamin A in response to SM (Fig. 7B), this cleavage was almost completely inhibited in keratinocytes that stably expressed FADD-DN. Thus, blocking the death receptor complex by expression of FADD-DN inhibits SM-induced internucleosomal DNA cleavage, as well as caspase-6-mediated nuclear lamin cleavage.

Expression of FADD-DN in Keratinocytes Suppresses SM-induced Cleavage of PARP and Caspase-7, an Effect That Is Dependent on Caspase-3-- To verify whether cleavage of downstream targets of caspase-3 is also blocked by expression of FADD-DN, immunoblot analysis was performed on extracts from control and SM-exposed cells with antibodies to PARP and caspase-7. Whereas both caspase-3-mediated cleavage of PARP and caspase-7 were observed following exposure of control Nco keratinocytes to 300 µM SM, these apoptotic markers were completely abolished by expression of FADD-DN (Fig. 8).


View larger version (28K):
[in this window]
[in a new window]
 
Fig. 8.   Expression of FADD-DN in Nco keratinocytes inhibits SM-induced PARP cleavage and proteolytic activation of caspase-7. Control or Nco keratinocytes stably expressing FADD-DN were exposed to 300 µM SM in SFM for 16 h, with or without a 30-min pretreatment of cells with a peptide inhibitor of caspase-3 (Ac-DEVD-CHO). Cell extracts were derived and subjected to immunoblot analysis with antibodies to FADD, PARP, caspase-7, and caspase-10. The positions of FADD and FADD-DN, as well as PARP, caspases-7 and -10, and their cleavage products are indicated.

To examine whether caspase-3 was in fact responsible for SM cytotoxicity in human keratinocytes, we next determined whether pretreatment of keratinocytes with the peptide inhibitor of caspase-3 (Ac-DEVD-CHO; Biomol) could block SM-induced cleavage of PARP and caspase 7. A 30-min pretreatment of cells with 50 µM Ac-DEVD-CHO prior to SM exposure suppressed activation of caspase-7 and PARP cleavage, which are both cleaved by caspase-3 (Fig. 8).

Inhibition of the Fas, but Not TNFR1, Pathway with Blocking Antibodies Inhibits Markers of SM-induced Apoptosis-- Elevation of both Fas and FasL suggested that activation of Fas is responsible for SM toxicity. To directly test the role of Fas and TNFR1 in SM-induced apoptosis, we utilized neutralizing antibodies specific for each receptor. Because phosphatidylserine is exposed on the surface of apoptotic cells, and the presence of these residues can be detected by their ability to bind to annexin V, we analyzed the cells for annexin V binding by FACS analysis 16 h after SM exposure. Fig. 9A shows that untreated NHEK are more sensitive to SM-induced apoptosis at the doses tested than those pretreated with Fas-blocking antibody (ZB4). A plot of the survival rates (propidium iodide negative, annexin V-negative) also confirms that control cells are more sensitive to SM-mediated killing (Fig. 9B). Fig. 9, C and D, further show that pretreatment of NHEK to ZB4 attenuates caspase-3 activity and proteolytic processing. In contrast, TNFR1-blocking antibody had no effect on SM-induced apoptotic markers and cell survival. Thus, SM exerts its effects primarily through a Fas-mediated pathway.


View larger version (16K):
[in this window]
[in a new window]
 
Fig. 9.   Inhibition of the Fas, but not TNFR1, pathway with blocking antibodies inhibits caspase-3 activity and processing. Human keratinocytes (NHEK) were incubated for 16 h with the indicated concentrations of SM in SFM in the presence or absence of Fas- or TNFR1-neutralizing antibodies, after which cells were prepared and assayed for annexin V binding plus propidium iodide staining by FACS analysis (A and B). Percentage of cells exhibiting annexin V binding (A) or that were negative for annexin V binding PI staining (B) as determined by FACS analysis are shown. All the data in A and B are presented as mean ± S.D. of three replicates of a representative experiment; essentially the same results were obtained in three independent experiments. Whole cell extracts were also prepared and assayed for caspase-3 activity with the specific substrate DEVD-AMC (C), or subjected to immunoblot analysis with antibodies specific for caspases-3 (D). The positions of the caspases and their proteolytic cleavage products are indicated.

FADD-DN Expression in Human Keratinocytes Partially Blocks the Vesication Response in Grafted Human Keratinocytes-- Human skin grafts transplanted onto nude mice have been used successfully to examine SM-induced biochemical alterations, utilizing an end point of micro- or macroblisters (1-6, 28). We also previously determined that NHEK as well as Nco cells could be used to establish a histologically and immunocytochemically normal epidermis when grafted onto nude mice that exhibits SM-induced vesication (8, 9, 15). Utilizing human keratin-specific antibodies, we additionally demonstrated the correct expression of human keratins K1, K10, and K14 within the grafted epidermis previously (15). In an attempt to test the effects of inhibitors of the death receptor pathway on apoptosis and vesication in intact human epidermis, we utilized this system to genetically engineer human keratinocytes prior to grafting to ectopically express FADD-DN. Nco and Nco-FADD-DN human grafts were subsequently exposed to SM by the vapor cup method 6-8 weeks after grafting. Frozen and fixed sections derived from graft sites of these animals were first analyzed for the expression of FADD-DN using the AU1 antibody, which recognizes the specific AU1 epitope on the FADD-DN protein. Immunofluorescence analysis of these sections with antibodies to FADD or AU1 verified that Nco keratinocytes stably expressing FADD-DN attached with an AU1 epitope tag could be grafted, and that the AU1 epitope could be detected within the grafted human skin (Fig. 10).


View larger version (37K):
[in this window]
[in a new window]
 
Fig. 10.   Detection of AU1-tagged FADD-DN and human K14 in human keratinocytes grafted to nude mice. A, schematic diagram of grafting protocol wherein a 1-cm diameter piece of skin is removed from the dorsal surface of athymic mice, and a pellet of cells containing 8 × 106 fibroblasts + 5 × 106 keratinocytes (NHEK or Nco) are pipetted on top of the muscular layer within a silicon dome to protect the cells during development. The dome is removed after 1 week. B, Nco human keratinocytes were stably transfected with a FADD-DN construct, containing a FADD-DN insert in pCDNA 3.1 linked to a sequence encoding the AU1 epitope. Six weeks after grafting, skin was harvested, fixed in formalin, and embedded in paraffin. 5 µM sections were deparaffinized, and stained with antisera specific for AU1 (middle), or human keratin 14 (right). No staining was observed in host mouse skin.

Significantly, histological analysis of SM-exposed animals grafted with Nco (control), and those grafted with the FADD-DN clone of Nco revealed that SM microvesication is reduced by FADD-DN. Table I shows that while there was no difference in the response of the athymic nude mouse host epidermis to SM (bottom half of Table I), there was a decrease in the amount of microvesication in the FADD-DN grafts (Table I, sixth column, boldface).

                              
View this table:
[in this window]
[in a new window]
 
Table I
Level of epidermal damage and microvesication in human skin grafts derived from Nco or Nco-FADD-DN keratinocytes
Numbers represent strength and severity of response and range from 0 to 4 (most severe).

SM Induces Markers of Apoptosis in Basal Cells in Human Skin Grafts, Particularly in Regions of Microvesication, an Effect That Is Inhibited by FADD-DN Expression-- Because the epidermis comprises less than half of the weight of the grafted skin, it is difficult to measure epidermal-specific markers of apoptosis by immunoblot analysis. We thus performed cytochemical and immunofluorescent analysis to examine the expression of markers within individual cells. In addition to increased sensitivity, cytochemical staining and immunofluorescent labeling of individual cells allowed us to localize and identify the cell type within the epidermis undergoing apoptosis (i.e. basal, spinous, granular, or cornified). This information coupled with the vesication data ultimately permits correlation between the apoptotic pathways and blistering.

DNA breaks can be detected in situ using a Klenow fragment-based assay system (DermaTACS; Trevigen). We tested the relationship between apoptotic DNA breaks, vesication, and the Fas/TNF pathway by two different approaches. In the first approach, we grafted control Nco keratinocytes, or FADD-DN-expressing Nco, followed by exposure to SM. 24 h after exposure, animals were sacrificed and skin biopsies were obtained, fixed, and sectioned. DNA breaks were then detected by the DermaTACS method as described under "Materials and Methods." Fig. 11A shows that SM induces apoptosis in basal cells of grafts derived from Nco. In addition, apoptotic cells were concentrated in the areas of microvesication. In contrast, Nco-FADD-DN skin grafts did not display the same degree of apoptosis or microvesication.


View larger version (75K):
[in this window]
[in a new window]
 
Fig. 11.   SM induces markers of apoptosis in basal cells in human skin grafts, particularly in regions of microvesication, an effect that is inhibited by Fas-knockout or FADD-DN expression. A, control human keratinocytes (Nco), or FADD-DN-expressing Nco were grafted onto nude mice, which were then exposed to SM by vapor cup. The SM-exposed human skin grafts were obtained, fixed, sectioned, and subjected to DNA break detection by DermaTACS. Slides were then observed by bright field microscopy. The positions of the basal cells, the dermis, and areas of vesication are indicated. B, control and Fas knockout newborn pups were exposed to SM by the vapor cup method. 24 h after exposure, animals were sacrificed, and skin biopsies were obtained, fixed, and sectioned. DNA breaks were then detected by the DermaTACS method as described under "Materials and Methods."

The second approach involved exposing control and Fas-knockout (lpr) newborn pups to SM by the vapor cup method. SM strongly induced apoptosis primarily in the basal cells of control animals in the areas of microvesication, but DNA breaks were markedly diminished in skin derived from genetically matched mice with a disrupted Fas gene (Fig 11B). Taken together, the data suggest that SM activates a Fas/TNF apoptotic pathway resulting in the activation of caspase-3 and apoptosis of basal cells, contributing to the vesication response.

To observe caspase-3 activation in skin sections, we performed immunofluorescent staining utilizing antibodies that recognize the cleavage products of caspase-3 but not the full-length protein to localize active caspase-3 in individual cells following exposure of human skin grafts to SM. Immunostaining of mouse epidermis exposed to SM by the vapor cup method using anti-active caspase-3 reveals that caspase-3 is activated in basal epidermal cells of control mouse skin treated with SM (Fig. 12). On the other hand, caspase-3 activation in basal cells was markedly diminished in skin derived from genetically matched mice with a disrupted Fas gene (knockout).2 These results suggest that the Fas/TNF pathway of apoptosis is activated in individual basal cells by SM, particularly in regions of microvesication. We also obtained similar results in which basal cells of SM-treated human skin grafts derived from Nco keratinocytes displayed immunostaining for active caspase-3 in areas of microvesication in the skin grafts. In contrast, preliminary results indicate that grafts derived from FADD-DN keratinocytes exhibit less active caspase-3 in the basal cells, consistent with the results of immunoblot analysis.2


View larger version (70K):
[in this window]
[in a new window]
 
Fig. 12.   Caspase-3 is activated in basal epidermal cells of mouse skin treated with SM by vapor cup, particularly in regions of microvesication. Newborn mice were exposed to SM by the vapor cup method, and paraffin-embedded sections were derived from the sites of SM-exposed mouse skin. Sections were deparaffinized, incubated with antibodies to active caspase-3 with biotinylated anti-mouse IgG, and with streptavidin-conjugated Texas Red, and then observed with a Zeiss fluorescence microscope as described under "Materials and Methods." Immunostaining of mouse epidermis treated with SM by vapor cup exposure using anti-active caspase-3 (left) or phase-contrast (right) are shown. The positions of the basal cells, cells with active caspases-3, as well as areas of microvesication are indicated.


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

SM vesication involves both cytotoxicity and detachment of the epidermal basal cell layer in vivo. Using a cell culture model in the present study, we have described a potential mechanism for SM-induced keratinocyte basal cell death and detachment: apoptosis in keratinocytes via a Fas/TNF death receptor pathway. Keratinocyte basal cell death is primarily because of apoptosis at the doses tested (100-300 µM SM), contributing to SM vesication (8). We have further observed the activation of markers of apoptosis that are consistent with a Fas ligand-receptor interaction, including caspase-8, caspase-3, and PARP cleavage (7-9). Several investigators have also examined the mode of cell death induced by SM in other cell types. SM induces an apoptotic response in HeLa cells (10-100 µM) (29), peripheral blood lymphocytes (6-300 µM) (30), keratinocytes (50-300 µM) (8, 17), and endothelial cells (<250 µM) (31). However, a time-dependent shift to necrosis was observed in SM-treated lymphocytes (30), whereas markers of necrosis were observed at higher levels of SM in endothelial cells (>500 µM) (31) and HeLa (1 mM) (29).

SM is a strong bifunctional alkylating agent with a high affinity for DNA, and has been shown to induce DNA strand breaks in keratinocytes (8, 32), which is confirmed by our results showing the presence of DNA breaks in SM-exposed human skin grafts. It is therefore likely that DNA strand breaks play a role in the SM-induced apoptosis in human keratinocytes. In an attempt to define the molecular series of events leading to SM vesication, we elucidated important pathways by which SM induces cell death in cultured keratinocytes, as well as in intact mouse and grafted human skin. Members of the Fas/TNFR family and their ligands may be induced at the level of transcription following stimulation by apoptosis-inducing agents, such as doxorubicin (19, 20), and p53 has been shown to play a role in the up-regulation of Fas (33). Consistently, we have shown that p53 is also rapidly up-regulated in keratinocytes following SM treatment, and that p53 may play a role in SM-induced apoptosis (9, 17). Similarly, ectopic overexpression of either Fas or FasL directly leads to apoptosis. In the present paper, we observed activation of a death receptor pathway for apoptosis, in which Fas receptor and FasL play a role. Following SM exposure, keratinocytes significantly up-regulate levels of both Fas receptor and FasL, followed by the rapid activation of the upstream caspase-8, mediated by recruitment of the adaptor protein FADD, and the consequent activation of the executioner caspases-3, -6, and -7.

To better understand the contribution of FADD-regulated pathways in the cutaneous response to SM, we blocked the death receptor pathway utilizing keratinocytes stably expressing a truncated FADD adaptor protein (FADD-DN); this protein lacks the N-terminal domain responsible for recruitment and activation of caspase-8 at the death receptor complex. Keratinocytes expressing FADD-DN exhibited reduced levels of FADD signaling and were found to be more resistant to SM-induced PARP cleavage and processing of caspases-3, -6, -7, and -8 into their active forms. In most apoptotic systems, caspase-3, the primary executioner caspase, is proteolytically activated, and in turn cleaves key proteins involved in the structure and integrity of the cell, including PARP, DFF 45, fodrin, gelsolin, receptor-interacting protein, X-linked inhibitor of apoptosis protein, topoisomerase I, vimentin, Rb, and lamin B (11-14, 34). Caspase-3 is also essential for apoptosis-associated chromatin margination, DNA fragmentation, and nuclear collapse (34).

Utilizing the stable expression of a dominant-negative inhibitor of FADD, we also demonstrated a role for the Fas/TNF receptor family in mediating the response of grafted human keratinocytes to SM. Significantly, we noted that blocking the Fas/FADD death receptor pathway in human skin grafted onto nude mice reduces vesication and tissue injury in response to SM, thus indicating that this pathway is an excellent target for therapeutic intervention to reduce SM injury. Fas-blocking antibody experiments in cultured keratinocytes also show that SM partially exerts its apoptotic effect via a Fas-FasL interaction (Fig. 9). In addition, our recent studies with Fas-deficient mice indicate the viability of this strategy to prevent vesication by using inhibitors of the death receptor pathway.

Both SM and UV, another agent that induces apoptosis in keratinocytes, have been shown to up-regulate the levels of another member of the Fas/TNF family, TNFalpha , and partial protection of keratinocytes from UV can be obtained by incubating keratinocytes with antibody that neutralizes TNF (35, 36). Targeted gene disruption (knockout) studies have shown that the majority of pathophysiological responses to TNFalpha are mediated by the p55 TNF receptor (TNFR1) (37, 38). TNFalpha was also shown to be elevated in SM-treated epidermal cells (39), and TNFalpha -blocking treatments have demonstrated a clinical usefulness for a wide variety of lesions, including systemic lupus erythematosus (40), rheumatoid arthritis (41), psoriasis (42-45), and cutaneous necrosis. However, in the current study, TNFR1-neutralizing antibody was unable to block SM-induced apoptosis.

An understanding of the mechanisms for SM-induced cell death in keratinocytes will hopefully lead to strategies for prevention or treatment of SM vesication. The present study suggests that inhibition of FADD (upstream) or caspase-3 (downstream) may alter the response of the epidermis to SM. With an understanding of the biochemical pathways for SM vesication and having attenuated SM-induced toxicity in vivo using a genetic approach, we are currently further testing the effects of specific pharmaceutical inhibitors of Fas/caspase death receptor pathway of apoptosis to block this pathway, and alter the cytotoxic response of keratinocytes to SM in cell culture, as well as the vesication response in vivo. To assay whether the SM-induced apoptotic response is altered upon treatment with inhibitors of the Fas/caspase pathway, we are examining the biochemical, morphological, and structural changes that we have previously established as characteristic markers of apoptosis (7, 8, 17). Our present study shows that we can detect activation of caspase-3 in single cells, thus, whether other caspases of the Fas/TNF receptor pathway are coactivated by SM in vivo, and whether this activation can be prevented by using inhibitors of this pathway, also remain to be clarified.

Toxic epidermal necrolysis, a blistering lesion similar to that resulting from SM exposure, has been successfully treated with intravenous immunoglobulins, containing naturally occurring neutralizing antibodies specific for human-Fas (46). FasL blocking antibodies, 5 mg/kg, injected into the tail vein, have also been shown to be effective in blocking ethanol-induced liver apoptosis in mice (47). Using antibodies that have been clinically used for other lesions, such as toxic epidermal necrolysis, systemic lupus erythematosus, rheumatoid arthritis, and psoriasis (40-46), we are currently testing the effects of inhibiting Fas/TNF binding to their ligands with neutralizing antibodies to Fas/TNFR in grafted human epidermis.

The effects of suppressing the function of the upstream caspases-8 and -9 as well as the downstream central execution caspase-3 with cell-permeable peptide inhibitors are also currently being investigated. An inhibitor that blocks the activity of all caspases, N-benzyloxycarbonyl-Val-Ala-Asp-(O-methyl)-fluoromethyl ketone (zVAD-fmk) has been used in a number of cell culture studies and in mouse in vivo studies. For example, three intraperitoneal injections of 0.25 mg/mouse on days 0, 5, and 10 were recently found to be sufficient to prevent silicosis (48). For in vivo inhibition of Fas/TNFR, systemically administered neutralizing antibodies against Fas/TNF, as well as systemic and topical peptide inhibitors of caspases are presently being evaluated. The use of pharmacological Fas/TNF/caspase inhibitors to study SM pathology, in the context of the whole animal grafted with human skin offers a better understanding of the mechanism of this damage for human personnel.

    ACKNOWLEDGEMENTS

We are grateful to Wen Fang Liu and Ruibai Luo for technical assistance.

    FOOTNOTES

* This work was supported by United States Army Medical Research and Materiel Command contract DAMD17-00-C-0026 (to D. S. R.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

§ To whom correspondence should be addressed: Dept. of Biochemistry and Molecular Biology, Georgetown University School of Medicine, 3900 Reservoir Rd. NW, Washington, D. C. 20007. Tel.: 202-687-1056; Fax: 202-687-7186; E-mail: rosenthd@georgetown.edu.

Published, JBC Papers in Press, December 12, 2002, DOI 10.1074/jbc.M209549200

2 D. S. Rosenthal, A. Velena, F-P. Chou, R. Schlegel, R. Ray, B. Benton, D. Anderson, W. J. Smith, and C. M. Simbulan-Rosenthal, unpublished data.

    ABBREVIATIONS

The abbreviations used are: SM, sulfur mustard; NHEK, normal human epidermal keratinocytes; FADD, Fas-associated death domain; DN, dominant-negative; PARP, poly(ADP-ribose) polymerase; FasL, Fas ligand; TNF, tumor necrosis factor; TNFR, tumor necrosis factor receptor; SFM, serum-free medium; CHAPS, 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonic acid; AMC, aminomethylcoumarin; DFF, DNA fragmentation factor; FACS, fluorescence-activated cell sorter; PBS, phosphate-buffered saline.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

1. Papirmeister, B., Feister, A. J., Robinson, S. I., and Ford, R. D. (1991) Medical Defense Against Mustard Gas: Toxic Mechanisms and Pharmacological Implications , 1st Ed. , CRC Press, Boca Raton, FL
2. Meier, H. L., Gross, C. L., Papirmeister, B., and Daszkiewicz, J. E. (1984) Proceedings of the Fourth Annual Chemical Defense Bioscience Review, Aberdeen Proving Ground, MD, May 30-June 1, 1984 , U. S. Army Medical Research Institute of Chemical Defense, Aberdeen Proving Ground, MD
3. Gross, C. L., Innace, J. K., Smith, W. J., Krebs, R. C., and Meier, H. L. (1988) Proceedings of the Meeting of NATO Research Study Group, Panel VIII/RSG-3, Washington, D. C., September 25-29, 1988 , NATO, Brussels, Belgium
4. Petrali, J. P., Oglesby, S. B., and Mills, K. R. (1990) J. Toxicol. Cutaneus Ocul. Toxicol. 9, 193-214
5. Smith, W. J., Gross, C. L., Chan, P., and Meier, H. L. (1990) Cell Biol. Toxicol. 6, 285-291[Medline] [Order article via Infotrieve]
6. Smith, W. J., and Dunn, M. A. (1991) Arch. Dermatol. 127, 1207-1213[Abstract]
7. Rosenthal, D. S., Simbulan-Rosenthal, C. M., Liu, W. F., Velena, A., Anderson, D., Benton, B., Wang, Z. Q., Smith, W., Ray, R., and Smulson, M. E. (2001) J. Invest. Dermatol. 117, 1566-1573[Abstract/Free Full Text]
8. Rosenthal, D. S., Simbulan-Rosenthal, C. M., Iyer, S., Spoonde, A., Smith, W., Ray, R., and Smulson, M. E. (1998) J. Invest. Dermatol. 111, 64-71[Abstract]
9. Rosenthal, D. S., Simbulan-Rosenthal, C. M., Iyer, S., Smith, W. J., Ray, R., and Smulson, M. E. (2000) J. Appl. Toxicol. 20, S43-S49[Medline] [Order article via Infotrieve]
10. Alnemri, E., Livingston, D., Nicholson, D., Salvesen, G., Thornberry, N., Wong, W., and Yuan, J. (1996) Cell 87, 171[Medline] [Order article via Infotrieve]
11. Nicholson, D. W., Ali, A., Thornberry, N. A., Vaillancourt, J. P., Ding, C. K., Gallant, M., Gareau, Y., Griffin, P. R., Labelle, M., Lazebnik, Y. A., Munday, N. A., Raju, S. M., Smulson, M. E., Yamin, T. T., Yu, V. L., and Miller, D. K. (1995) Nature 376, 37-43[CrossRef][Medline] [Order article via Infotrieve]
12. Tewari, M., Quan, L. T., O'Rourke, K., Desnoyers, S., Zeng, Z., Beidler, D. R., Poirier, G. G., Salvesen, G. S., and Dixit, V. M. (1995) Cell 81, 801-809[Medline] [Order article via Infotrieve]
13. Song, Q., Lees-Miller, S., Kumar, S., Zhang, Z., Chan, D., Smith, G., Jackson, S., Alnemri, E., Litwack, G., Khanna, K., and Lavin, M. (1996) EMBO J. 15, 3238-3246[Abstract]
14. Casciola-Rosen, L., Nicholson, D., Chong, T., Rowan, K., Thornberry, N., Miller, D., and Rosen, A. (1996) J. Exp. Med. 183, 1957-1964[Abstract]
15. Rosenthal, D. S., Shima, T. B., Celli, G., De Luca, L. M., and Smulson, M. E. (1995) J. Invest. Dermatol. 105, 38-44[Abstract]
16. Sherman, L., and Schlegel, R. (1996) J. Virol. 70, 3269-3279[Abstract]
17. Stöppler, H., Stöppler, M. C., Johnson, E., Simbulan-Rosenthal, C. M., Smulson, M. E., Iyer, S., Rosenthal, D. S., and Schlegel, R. (1998) Oncogene 17, 1207-1214[CrossRef][Medline] [Order article via Infotrieve]
18. Choi, K. B., Wong, F., Harlan, J. M., Chaudhary, P. M., Hood, L., and Karsan, A. (1998) J. Biol. Chem. 273, 20185-20188[Abstract/Free Full Text]
19. Herr, I., Wilhelm, D., Bohler, T., Angel, P., and Debatin, K. M. (1997) EMBO J. 16, 6200-6208[Abstract/Free Full Text]
20. Friesen, C., Herr, I., Krammer, P. H., and Debatin, K. M. (1996) Nat. Med. 2, 574-577[Medline] [Order article via Infotrieve]
21. Ruchaud, S. N. K., Villa, P., Kottke, T., Dingwall, C. S. K., and Earnshaw, W. (2002) EMBO J. 21, 1967-1977[Abstract/Free Full Text]
22. McLean, W. H., Eady, R. A., Dopping-Hepenstal, P. J., McMillan, J. R., Leigh, I. M., Navsaria, H. A., Higgins, C., Harper, J. I., Paige, D. G., Morley, S. M., and Lane, E. B. (1994) J. Invest. Dermatol. 102, 24-30[Abstract]
23. Takahashi, H., Kobayashi, H., Hashimoto, Y., Matsuo, S., and Iizuka, H. (1995) J. Invest. Dermatol. 105, 810-815[Abstract]
24. Chinnaiyan, A. M., O'Rourke, K., Tewari, M., and Dixit, V. M. (1995) Cell 81, 505-512[Medline] [Order article via Infotrieve]
25. Imai, Y., Kimura, T., Murakami, A., Yajima, N., Sakamaki, K., and Yonehara, S. (1999) Nature 398, 777-785[CrossRef][Medline] [Order article via Infotrieve]
26. Medema, J. P., Scaffidi, C., Kischkel, F. C., Shevchenko, A., Mann, M., Krammer, P. H., and Peter, M. E. (1997) EMBO J. 16, 2794-2804[Abstract/Free Full Text]
27. Kischkel, F. C., Hellbardt, S., Behrmann, I., Germer, M., Pawlita, M., Krammer, P. H., and Peter, M. E. (1995) EMBO J. 14, 5579-5588[Abstract]
28. van Genderen, J., Mol, M. A., and Wolthuis, O. L. (1985) Fundam. Appl. Toxicol. 5, S98-S111[Medline] [Order article via Infotrieve]
29. Sun, J., Wang, Y. X., and Sun, M. J. (1999) Chung Kuo Yao Li Hsueh Pao 20, 445-448[Medline] [Order article via Infotrieve]
30. Meier, H. L., and Millard, C. B. (1998) Biochim. Biophys. Acta 1404, 367-376[Medline] [Order article via Infotrieve]
31. Dabrowska, M. I., Becks, L. L., Lelli, J. L., Jr., Levee, M. G., and Hinshaw, D. B. (1996) Toxicol. Appl. Pharmacol. 141, 568-583[CrossRef][Medline] [Order article via Infotrieve]
32. Hinshaw, D. B., Lodhi, I. J., Hurley, L. L., Atkins, K. B., and Dabrowska, M. I. (1999) Toxicol. Appl. Pharmacol. 156, 17-29[CrossRef][Medline] [Order article via Infotrieve]
33. Owen-Schaub, L. B., Zhang, W., Cusack, J. C., Angelo, L. S., Santee, S. M., Fujiwara, T., Roth, J. A., Deisseroth, A. B., Zhang, W. W., Kruzel, E., and Radinsky, R. (1995) Mol. Cell. Biol. 15, 3032-3040[Abstract]
34. Slee, E., Adrain, C., and Martin, S. (2001) J. Biol. Chem. 276, 7320-7326[Abstract/Free Full Text]
35. Schwarz, A., Bhardwaj, R., Aragane, Y., Mahnke, K., Riemann, H., Metze, D., Luger, T. A., and Schwarz, T. (1995) J. Invest. Dermatol. 104, 922-927[Abstract]
36. Schwarz, A., Mahnke, K., Luger, T. A., and Schwarz, T. (1997) Exp. Dermatol. 6, 1-5[Medline] [Order article via Infotrieve]
37. Zhuang, L., Wang, B., Shinder, G. A., Shivji, G. M., Mak, T. W., and Sauder, D. N. (1999) J. Immunol. 162, 1440-1447[Abstract/Free Full Text]
38. Zhuang, L., Wang, B., and Sauder, D. N. (2000) J. Interferon Cytokine Res. 20, 445-454[CrossRef][Medline] [Order article via Infotrieve]
39. Arroyo, C. M., Schafer, R. J., Kurt, E. M., Broomfield, C. A., and Carmichael, A. J. (2000) J. Appl. Toxicol. 20 Suppl. 1, S63-S72[Medline] [Order article via Infotrieve]
40. Aringer, M., Feierl, E., Steiner, G., Stummvoll, G. H., Hofler, E., Steiner, C. W., Radda, I., Smole, J. S., and Graninger, W. B. (2002) Lupus 11, 102-108[CrossRef][Medline] [Order article via Infotrieve]
41. Butler, D. M., Maini, R. N., Feldmann, M., and Brennan, F. M. (1995) Eur. Cytokine Netw. 6, 225-230[Medline] [Order article via Infotrieve]
42. Mang, R., Stege, H., Ruzicka, T., and Krutmann, J. (2002) Dermatology 204, 156-157[Medline] [Order article via Infotrieve]
43. Schopf, R. E., Aust, H., and Knop, J. (2002) J. Am. Acad. Dermatol. 46, 886-891[CrossRef][Medline] [Order article via Infotrieve]
44. O'Quinn, R. P., and Miller, J. L. (2002) Arch. Dermatol. 138, 644-648[Abstract/Free Full Text]
45. Scallon, B., Cai, A., Solowski, N., Rosenberg, A., Song, X. Y., Shealy, D., and Wagner, C. (2002) J. Pharmacol. Exp. Ther. 301, 418-426[Abstract/Free Full Text]
46. Viard, I., Wehrli, P., Bullani, R., Schneider, P., Holler, N., Salomon, D., Hunziker, T., Saurat, J. H., Tschopp, J., and French, L. E. (1998) Science 282, 490-493[Abstract/Free Full Text]
47. Zhou, Z., Sun, X., and Kang, Y. J. (2001) Am. J. Pathol. 159, 329-338[Abstract/Free Full Text]
48. Borges, V. M., Lopes, M. F., Falcao, H., Leite-Junior, J. H., Rocco, P. R., Davidson, W. F., Linden, R., Zin, W. A., and DosReis, G. A. (2002) Am. J. Respir. Cell Mol. Biol. 27, 78-84[Abstract/Free Full Text]


Copyright © 2003 by The American Society for Biochemistry and Molecular Biology, Inc.